24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
L-GANASELIEVA 5000IU is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | L-GANASELIEVA 5000IU |
|---|---|
| Composition | L-Asparaginase Injection 5000IU |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
L-GANASELIEVA 5000IU (L-Asparaginase Injection 5000IU) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
L-GANASELIEVA 5000 IU (L-Asparaginase Injection 5000 IU) is a prescription anticancer medicine used in the treatment of Acute Lymphoblastic Leukemia (ALL) and certain other hematological malignancies. It contains L-Asparaginase 5000 IU, an enzyme-based chemotherapy medicine that works by reducing the availability of asparagine, an amino acid required for the growth and survival of specific cancer cells.
Acute Lymphoblastic Leukemia is a type of blood cancer that affects white blood cells and is commonly diagnosed in children, although it can also occur in adults. Leukemia cells depend heavily on asparagine to survive and multiply. Unlike normal cells, these cancer cells often cannot produce sufficient amounts of asparagine on their own. L-GANASELIEVA 5000 IU helps destroy leukemia cells by breaking down circulating asparagine, effectively starving cancer cells and slowing their growth.
L-Asparaginase has been an essential component of leukemia treatment protocols for decades and is frequently included in combination chemotherapy regimens. Its unique mechanism of action complements other anticancer medicines and contributes significantly to successful treatment outcomes.
L-GANASELIEVA 5000 IU is commonly prescribed for:
The medicine is generally administered under strict medical supervision in hospitals, oncology centers, and specialized hematology treatment facilities. Treatment schedules vary depending on the patient's age, disease stage, treatment protocol, and overall health condition.
Manufactured under stringent pharmaceutical quality standards, L-GANASELIEVA 5000 IU is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology care.
Patients receiving L-Asparaginase therapy often require regular blood tests, liver function monitoring, pancreatic assessments, coagulation studies, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven role in leukemia management, L-GANASELIEVA 5000 IU remains an important medicine in modern hematology and pediatric oncology treatment programs worldwide.
L-GANASELIEVA 5000 IU (L-Asparaginase Injection 5000 IU) is primarily used for the treatment and management of leukemia and related blood cancers.
The medicine is widely used as part of standard treatment protocols for acute lymphoblastic leukemia.
L-Asparaginase is commonly included in childhood leukemia treatment programs.
The medicine may also be prescribed for adults diagnosed with ALL.
L-GANASELIEVA is often used alongside other chemotherapy medicines to improve treatment outcomes.
The medicine may be included in treatment plans for selected blood-related cancers.
It supports comprehensive leukemia treatment strategies and long-term disease management.
L-Asparaginase belongs to a class of medicines known as enzyme-based antineoplastic agents.
L-GANASELIEVA works by:
This unique mechanism helps target leukemia cells while supporting comprehensive cancer management.
Like all prescription medicines, L-GANASELIEVA 5000 IU may cause side effects in some patients. Side effects vary depending on individual response and treatment duration.
Patients may experience mild to moderate nausea during treatment.
Episodes of vomiting may occur in some individuals.
Weakness and tiredness are commonly reported.
Mild fever may develop during therapy.
Reduced appetite may affect nutritional intake.
Pain, redness, swelling, or irritation may occur at the injection site.
Some patients may experience stomach discomfort.
Temporary changes in liver function tests may occur.
The medicine may affect normal blood clotting mechanisms.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of L-GANASELIEVA 5000 IU (L-Asparaginase Injection 5000 IU) should always be determined by a qualified oncologist or hematologist.
Treatment schedules vary depending on the diagnosed condition.
Pediatric and adult dosing protocols may differ significantly.
Dosage is often calculated according to body size.
The medicine is frequently administered as part of multi-drug chemotherapy regimens.
Doctors may modify therapy based on effectiveness and tolerability.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of Acute Lymphoblastic Leukemia (ALL) and selected hematological malignancies.
L-Asparaginase is an enzyme-based anticancer medicine that reduces asparagine levels required by leukemia cells for survival.
Yes, it is an anticancer medicine commonly used as part of combination chemotherapy treatment protocols.
Yes, it is widely used in pediatric leukemia treatment programs under specialist supervision.
Yes, liver function monitoring is often required during treatment.
Blood tests help monitor treatment response, liver health, clotting status, and overall safety.
No, treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in hematology, pediatric oncology, and cancer treatment.